Searched for
PIRAMAL PHARMA
Pharma stocks slide as Trump's 100% generic drug tariff plan spooks investorsIndian drug shares declined Wednesday following US President Trump's tariff announcement. These proposed tariffs will significantly impact ...- Why did market fall today? 7 triggers behind Rs 4 lakh crore wealth wipeoutIndian stock markets experienced significant declines on Wednesday. Escalating Iran-US tensions and tariff threats spooked investors, causi...
- Two Trades for Today: A mid-cap pharma stock for a 8.69% upmove, a South India-focused private bank for a 7% gainOur technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...
- Mutual funds boost equity bets in June, favour largecaps and private banksFund houses experienced robust equity inflows during June. Money managers favored large-cap stocks trading below historical averages. Priva...
- JioBlackRock Flexi Cap Fund exits Vedanta group companies after demerger, sells 8 more stocksJioBlackRock Flexi Cap Fund exited Vedanta group companies following the demerger of the entities in June, according to monthly portfolio d...
- Airtel to Trent: 44 cos likely to report double-digit profit slump in Q1. Are your stocks on the list?Motilal Oswal expects 44 companies, including Bharti Airtel, Trent, IndiGo, HAL, GAIL and Cipla, to report double-digit year-on-year profit...
- Analysts back buy on dips strategy as Nifty targets 24,450–24,800Indian stock market analysts are optimistic, anticipating the Nifty to continue its upward trend. They suggest buying on dips around the 24...
- Swara Baby files DRHP with Sebi for Rs 1,000 crore IPOSwara Baby has filed its DRHP with Sebi for a Rs 1,000 crore IPO, comprising a Rs 500 crore fresh issue and Rs 500 crore OFS. The hygiene p...
- Ahead of Market: 10 things that will decide stock market action on WednesdaySensex and Nifty plunged over 1% on Tuesday amid global market weakness, IT sector losses, a weaker rupee and fresh foreign fund outflows. ...
- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsFrom a macro perspective, it is clearly a good time to be bullish. But as valuations remain high in parts of the market despite the recent ...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 27% in 1 yearAfter the correction, the street will reach a stage where, if a company delivers numbers, there will be enough money waiting to move into t...
- Q4 earnings roundup: Raymond Realty, MCX among 19 companies that delivered 100%+ growth in sales and PATA select group of 19 large-cap BSE-listed companies achieved triple-digit growth in both profit and revenue during Q4FY26, indicating stron...
- Positive Breakout: These 11 stocks cross above their 200 DMAsAs long as the stock is priced above the 200-day SMA on the daily time frame, it is generally considered to be an overall uptrend.
- Vedanta demerger: What recent large demergers of Tata Motors, ITC and others tell us about possible listing timeline?Vedanta's mega demerger has created four new entities, with investors eagerly awaiting their stock market listings. Drawing parallels from ...
- Positive Breakout: These 7 stocks cross above their 200 DMAsAs long as the stock is priced above the 200-day SMA on the daily timeframe, it is generally considered to be in an overall uptrend.
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Nandini Piramal warns prolonged West Asia war may raise input costsGeopolitical tensions in West Asia are manageable now. However, a prolonged US-Israel war against Iran could raise costs for petrochemical-...
- Piramal Pharma targets to double revenue in 5 yearsPiramal Pharma aims to achieve $2 billion in annual revenue with a 25% operating margin by fiscal 2030, driven by its CDMO business. The co...
- After a tough year, Piramal Pharma hopes to regain vigour in 2nd halfPiramal Pharma chairperson Nandini Piramal in an interview to ET said the company is aiming for mid-teen revenue growth and a meaningful im...
Load More
